Cargando…

Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis

BACKGROUND: Nasya/Prevalin is a natural, drug-free nasal spray for treatment and prevention of allergic rhinitis. Because of its thixotropic property, it forms a barrier on the nasal mucosa, preventing allergen contact. This study assesses the clinical efficacy and safety of Nasya/Prevalin in a nasa...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoelzel, Katharina, Bothe, Gordana, Chong, Pee Win, Lenarz, Minoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235399/
https://www.ncbi.nlm.nih.gov/pubmed/24279907
http://dx.doi.org/10.1111/crj.12080
_version_ 1782345020562472960
author Stoelzel, Katharina
Bothe, Gordana
Chong, Pee Win
Lenarz, Minoo
author_facet Stoelzel, Katharina
Bothe, Gordana
Chong, Pee Win
Lenarz, Minoo
author_sort Stoelzel, Katharina
collection PubMed
description BACKGROUND: Nasya/Prevalin is a natural, drug-free nasal spray for treatment and prevention of allergic rhinitis. Because of its thixotropic property, it forms a barrier on the nasal mucosa, preventing allergen contact. This study assesses the clinical efficacy and safety of Nasya/Prevalin in a nasal provocation test with house dust mite allergens. METHODOLOGY/PRINCIPAL: In this randomised, double-blind, placebo-controlled trial, 20 subjects suffering from allergic rhinitis because of house dust mite allergens received a single dose of Nasya/Prevalin or saline spray before allergen challenge. Total nasal symptom score and total ocular symptom score were assessed 15, 30, 60, 75, 90, 120 and 240 min after challenge. Further, the appearance of the mucosa was examined by rhinoscopy. RESULTS: A single treatment with Nasya/Prevalin led to a significant reduction of TNSS at 60, 75 and 90 min after dust mite allergen challenge as compared with placebo (p(VCAS) = 0.021, p(VCAS) = 0.035, p(VCAS) = 0.036, respectively). Mucosa changes assessed by the rhinoscopic score (on swelling, secretion and colour) were significantly worse in the placebo group compared with the Nasya/Prevalin group (P = 0.033). Nasya/Prevalin was well tolerated, and the safety was comparable with placebo. CONCLUSIONS: Treatment with Nasya/Prevalin was effective in preventing allergic reactions induced by dust mite allergen challenge. Please cite this paper as: Stoelzel K, Bothe G, Chong PW and Lenarz M. Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis. Clin Respir J 2014; 8: 382–390.
format Online
Article
Text
id pubmed-4235399
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42353992014-12-15 Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis Stoelzel, Katharina Bothe, Gordana Chong, Pee Win Lenarz, Minoo Clin Respir J Original Articles BACKGROUND: Nasya/Prevalin is a natural, drug-free nasal spray for treatment and prevention of allergic rhinitis. Because of its thixotropic property, it forms a barrier on the nasal mucosa, preventing allergen contact. This study assesses the clinical efficacy and safety of Nasya/Prevalin in a nasal provocation test with house dust mite allergens. METHODOLOGY/PRINCIPAL: In this randomised, double-blind, placebo-controlled trial, 20 subjects suffering from allergic rhinitis because of house dust mite allergens received a single dose of Nasya/Prevalin or saline spray before allergen challenge. Total nasal symptom score and total ocular symptom score were assessed 15, 30, 60, 75, 90, 120 and 240 min after challenge. Further, the appearance of the mucosa was examined by rhinoscopy. RESULTS: A single treatment with Nasya/Prevalin led to a significant reduction of TNSS at 60, 75 and 90 min after dust mite allergen challenge as compared with placebo (p(VCAS) = 0.021, p(VCAS) = 0.035, p(VCAS) = 0.036, respectively). Mucosa changes assessed by the rhinoscopic score (on swelling, secretion and colour) were significantly worse in the placebo group compared with the Nasya/Prevalin group (P = 0.033). Nasya/Prevalin was well tolerated, and the safety was comparable with placebo. CONCLUSIONS: Treatment with Nasya/Prevalin was effective in preventing allergic reactions induced by dust mite allergen challenge. Please cite this paper as: Stoelzel K, Bothe G, Chong PW and Lenarz M. Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis. Clin Respir J 2014; 8: 382–390. BlackWell Publishing Ltd 2014-10 2013-12-23 /pmc/articles/PMC4235399/ /pubmed/24279907 http://dx.doi.org/10.1111/crj.12080 Text en © 2013 John Wiley & Sons Ltd http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Stoelzel, Katharina
Bothe, Gordana
Chong, Pee Win
Lenarz, Minoo
Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis
title Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis
title_full Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis
title_fullStr Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis
title_full_unstemmed Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis
title_short Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis
title_sort safety and efficacy of nasya/prevalin in reducing symptoms of allergic rhinitis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235399/
https://www.ncbi.nlm.nih.gov/pubmed/24279907
http://dx.doi.org/10.1111/crj.12080
work_keys_str_mv AT stoelzelkatharina safetyandefficacyofnasyaprevalininreducingsymptomsofallergicrhinitis
AT bothegordana safetyandefficacyofnasyaprevalininreducingsymptomsofallergicrhinitis
AT chongpeewin safetyandefficacyofnasyaprevalininreducingsymptomsofallergicrhinitis
AT lenarzminoo safetyandefficacyofnasyaprevalininreducingsymptomsofallergicrhinitis